Radiopharm Theranostics Limited American Depositary Shares Total Assets
Radiopharm Theranostics Limited American Depositary Shares total assets. Based on the latest financial reports, Radiopharm Theranostics Limited American Depositary Shares (RADX) holds total assets worth $60.14 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Radiopharm Theranostics Limited American market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Radiopharm Theranostics Limited American Depositary Shares (2022–2026)
Total assets of Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2026. This chart illustrates how Radiopharm Theranostics Limited American Depositary Shares's total assets have evolved over time, based on quarterly financial data. See Radiopharm Theranostics Limited American share price for real-time trading data and today's change.
Radiopharm Theranostics Limited American Depositary Shares - Asset Composition Analysis
Radiopharm Theranostics Limited American Depositary Shares Total Assets Breakdown (June 2026)
Radiopharm Theranostics Limited American Depositary Shares total assets breakdown as of June 2026. Radiopharm Theranostics Limited American Depositary Shares's total assets of $60.14 Million consist of 36.5% current assets and 63.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.9% |
| Accounts Receivable | $17.45 Million | 29.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2026)
This chart illustrates how Radiopharm Theranostics Limited American Depositary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Radiopharm Theranostics Limited American (RADX) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Radiopharm Theranostics Limited American Depositary Shares's current assets represent 36.5% of total assets in 2026, an increase from 32.7% in 2022.
- Cash Position: Cash and equivalents constituted 6.9% of total assets in 2026, down from 32.4% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 67.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 29.0% of total assets.
Radiopharm Theranostics Limited American Depositary Shares Competitors by Total Assets
Key competitors of Radiopharm Theranostics Limited American Depositary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Radiopharm Theranostics Limited American Depositary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.16 | 0.50 | 3.46 |
| Quick Ratio | 1.16 | 0.50 | 3.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.03 Million | $-6.38 Million | $19.39 Million |
Radiopharm Theranostics Limited American Depositary Shares - Advanced Valuation Insights
This section examines the relationship between Radiopharm Theranostics Limited American Depositary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.67 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -30.5% |
| Total Assets | $60.14 Million |
| Market Capitalization | $12.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Radiopharm Theranostics Limited American Depositary Shares's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Radiopharm Theranostics Limited American Depositary Shares's assets decreased by 30.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Radiopharm Theranostics Limited American Depositary Shares (2022–2026)
The table below shows the annual total assets of Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | $60.14 Million | -30.46% |
| 2025-06-30 | $86.48 Million | +20.05% |
| 2024-06-30 | $72.04 Million | -3.89% |
| 2023-06-30 | $74.95 Million | -10.11% |
| 2022-06-30 | $83.38 Million | -- |
About Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more